Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05889390 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer

Study acronym: NeoHTerMa
StatusActive, Not Recruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date changed from estimate of May 31, 2025 to Oct 31, 2025
    • Study completion date: Aug 31, 2025 to Dec 31, 2026
    v3
  2. Trial status: Recruiting to Active, Not Recruitingv2 Show 4 more changesShow less
    • Enrollment target: estimated 120 to confirmed 71
    • Primary completion date: Dec 31, 2024 to May 31, 2025
    • Study completion date: Apr 30, 2025 to Aug 31, 2025
    • Site details revised
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study is to investigate whether the application of concomitant modulated electro-hyperthermia in a neoadjuvant chemotherapeutic setting is beneficial for patients with HER2-negative, stage II-III breast cancer.
Trial Details
NCT Number NCT05889390
Lead Sponsor Semmelweis University
Conditions
(from sponsor)		 HER2-negative Breast Cancer
Related terms Breast Neoplasms, Hyperthermia
Enrollment 71 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov